Quality of life in head and neck cancer patients

Impact of HPV and primary treatment modality

Jessica H. Maxwell, Vikas Mehta, Hong Wang, Diana Cunningham, Umamaheswar Duvvuri, Seungwon Kim, Jonas Johnson, Robert L. Ferris

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objectives/Hypothesis To determine posttreatment quality of life (QOL) in head and neck cancer patients, stratifying by human papillomavirus (HPV)/p16 status and primary treatment modality. Study Design Retrospective study. Methods One hundred and seventy-seven patients (N=177) with head and neck squamous cell carcinoma and known HPV/p16 status were included. All patients completed at least one baseline or posttreatment University of Washington QOL survey. QOL scores were averaged and compared across patients, stratifying by HPV/p16 status and primary treatment modality (surgical vs. nonsurgical). In the analysis, p16 was used as a surrogate marker for HPV. Results Of the 177 patients, 80 (45.2%) were p16-positive and 49.7% of subsites were oropharyngeal. Nearly 60% (105/177) of patients underwent primary surgery, 26.7% (28/105) of patients with transoral robotic or laser techniques. The remainder 40.7% of patients underwent primary radiation and/or chemotherapy. Overall, QOL scores were better for p16-positive patients compared to p16-negative patients at baseline (P=0.008), at 6 months posttreatment (P=0.034), and at greater than 1 year posttreatment (P=0.013). P16-positive patients had better QOL scores in speech (P=0.0009), chewing (P=0.0004), and swallowing (P=0.021) after 1 year posttreatment compared to p16-negative patients. Primary treatment modality did not affect overall QOL or any of the 12 QOL categories in p16-positive patients at any time point. At over 1 year posttreatment, QOL was at or above baseline in both p16-positive treatment groups. Conclusion The p16-positive patients had better baseline and posttreatment overall QOL compared to p16-negative patients. The overall and category specific QOL scores for p16-positive patients were not affected by primary treatment modality. Level of Evidence 4. Laryngoscope, 124:1592-1597, 2014

Original languageEnglish (US)
Pages (from-to)1592-1597
Number of pages6
JournalLaryngoscope
Volume124
Issue number7
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Head and Neck Neoplasms
Quality of Life
Therapeutics
Laryngoscopes
Mastication
Robotics
Deglutition

Keywords

  • head and neck squamous cell carcinoma
  • HPV
  • p16
  • Quality of life

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Maxwell, J. H., Mehta, V., Wang, H., Cunningham, D., Duvvuri, U., Kim, S., ... Ferris, R. L. (2014). Quality of life in head and neck cancer patients: Impact of HPV and primary treatment modality. Laryngoscope, 124(7), 1592-1597. https://doi.org/10.1002/lary.24508

Quality of life in head and neck cancer patients : Impact of HPV and primary treatment modality. / Maxwell, Jessica H.; Mehta, Vikas; Wang, Hong; Cunningham, Diana; Duvvuri, Umamaheswar; Kim, Seungwon; Johnson, Jonas; Ferris, Robert L.

In: Laryngoscope, Vol. 124, No. 7, 2014, p. 1592-1597.

Research output: Contribution to journalArticle

Maxwell, JH, Mehta, V, Wang, H, Cunningham, D, Duvvuri, U, Kim, S, Johnson, J & Ferris, RL 2014, 'Quality of life in head and neck cancer patients: Impact of HPV and primary treatment modality', Laryngoscope, vol. 124, no. 7, pp. 1592-1597. https://doi.org/10.1002/lary.24508
Maxwell, Jessica H. ; Mehta, Vikas ; Wang, Hong ; Cunningham, Diana ; Duvvuri, Umamaheswar ; Kim, Seungwon ; Johnson, Jonas ; Ferris, Robert L. / Quality of life in head and neck cancer patients : Impact of HPV and primary treatment modality. In: Laryngoscope. 2014 ; Vol. 124, No. 7. pp. 1592-1597.
@article{8ddb998c1d434af0b952f2b09fa232d1,
title = "Quality of life in head and neck cancer patients: Impact of HPV and primary treatment modality",
abstract = "Objectives/Hypothesis To determine posttreatment quality of life (QOL) in head and neck cancer patients, stratifying by human papillomavirus (HPV)/p16 status and primary treatment modality. Study Design Retrospective study. Methods One hundred and seventy-seven patients (N=177) with head and neck squamous cell carcinoma and known HPV/p16 status were included. All patients completed at least one baseline or posttreatment University of Washington QOL survey. QOL scores were averaged and compared across patients, stratifying by HPV/p16 status and primary treatment modality (surgical vs. nonsurgical). In the analysis, p16 was used as a surrogate marker for HPV. Results Of the 177 patients, 80 (45.2{\%}) were p16-positive and 49.7{\%} of subsites were oropharyngeal. Nearly 60{\%} (105/177) of patients underwent primary surgery, 26.7{\%} (28/105) of patients with transoral robotic or laser techniques. The remainder 40.7{\%} of patients underwent primary radiation and/or chemotherapy. Overall, QOL scores were better for p16-positive patients compared to p16-negative patients at baseline (P=0.008), at 6 months posttreatment (P=0.034), and at greater than 1 year posttreatment (P=0.013). P16-positive patients had better QOL scores in speech (P=0.0009), chewing (P=0.0004), and swallowing (P=0.021) after 1 year posttreatment compared to p16-negative patients. Primary treatment modality did not affect overall QOL or any of the 12 QOL categories in p16-positive patients at any time point. At over 1 year posttreatment, QOL was at or above baseline in both p16-positive treatment groups. Conclusion The p16-positive patients had better baseline and posttreatment overall QOL compared to p16-negative patients. The overall and category specific QOL scores for p16-positive patients were not affected by primary treatment modality. Level of Evidence 4. Laryngoscope, 124:1592-1597, 2014",
keywords = "head and neck squamous cell carcinoma, HPV, p16, Quality of life",
author = "Maxwell, {Jessica H.} and Vikas Mehta and Hong Wang and Diana Cunningham and Umamaheswar Duvvuri and Seungwon Kim and Jonas Johnson and Ferris, {Robert L.}",
year = "2014",
doi = "10.1002/lary.24508",
language = "English (US)",
volume = "124",
pages = "1592--1597",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Quality of life in head and neck cancer patients

T2 - Impact of HPV and primary treatment modality

AU - Maxwell, Jessica H.

AU - Mehta, Vikas

AU - Wang, Hong

AU - Cunningham, Diana

AU - Duvvuri, Umamaheswar

AU - Kim, Seungwon

AU - Johnson, Jonas

AU - Ferris, Robert L.

PY - 2014

Y1 - 2014

N2 - Objectives/Hypothesis To determine posttreatment quality of life (QOL) in head and neck cancer patients, stratifying by human papillomavirus (HPV)/p16 status and primary treatment modality. Study Design Retrospective study. Methods One hundred and seventy-seven patients (N=177) with head and neck squamous cell carcinoma and known HPV/p16 status were included. All patients completed at least one baseline or posttreatment University of Washington QOL survey. QOL scores were averaged and compared across patients, stratifying by HPV/p16 status and primary treatment modality (surgical vs. nonsurgical). In the analysis, p16 was used as a surrogate marker for HPV. Results Of the 177 patients, 80 (45.2%) were p16-positive and 49.7% of subsites were oropharyngeal. Nearly 60% (105/177) of patients underwent primary surgery, 26.7% (28/105) of patients with transoral robotic or laser techniques. The remainder 40.7% of patients underwent primary radiation and/or chemotherapy. Overall, QOL scores were better for p16-positive patients compared to p16-negative patients at baseline (P=0.008), at 6 months posttreatment (P=0.034), and at greater than 1 year posttreatment (P=0.013). P16-positive patients had better QOL scores in speech (P=0.0009), chewing (P=0.0004), and swallowing (P=0.021) after 1 year posttreatment compared to p16-negative patients. Primary treatment modality did not affect overall QOL or any of the 12 QOL categories in p16-positive patients at any time point. At over 1 year posttreatment, QOL was at or above baseline in both p16-positive treatment groups. Conclusion The p16-positive patients had better baseline and posttreatment overall QOL compared to p16-negative patients. The overall and category specific QOL scores for p16-positive patients were not affected by primary treatment modality. Level of Evidence 4. Laryngoscope, 124:1592-1597, 2014

AB - Objectives/Hypothesis To determine posttreatment quality of life (QOL) in head and neck cancer patients, stratifying by human papillomavirus (HPV)/p16 status and primary treatment modality. Study Design Retrospective study. Methods One hundred and seventy-seven patients (N=177) with head and neck squamous cell carcinoma and known HPV/p16 status were included. All patients completed at least one baseline or posttreatment University of Washington QOL survey. QOL scores were averaged and compared across patients, stratifying by HPV/p16 status and primary treatment modality (surgical vs. nonsurgical). In the analysis, p16 was used as a surrogate marker for HPV. Results Of the 177 patients, 80 (45.2%) were p16-positive and 49.7% of subsites were oropharyngeal. Nearly 60% (105/177) of patients underwent primary surgery, 26.7% (28/105) of patients with transoral robotic or laser techniques. The remainder 40.7% of patients underwent primary radiation and/or chemotherapy. Overall, QOL scores were better for p16-positive patients compared to p16-negative patients at baseline (P=0.008), at 6 months posttreatment (P=0.034), and at greater than 1 year posttreatment (P=0.013). P16-positive patients had better QOL scores in speech (P=0.0009), chewing (P=0.0004), and swallowing (P=0.021) after 1 year posttreatment compared to p16-negative patients. Primary treatment modality did not affect overall QOL or any of the 12 QOL categories in p16-positive patients at any time point. At over 1 year posttreatment, QOL was at or above baseline in both p16-positive treatment groups. Conclusion The p16-positive patients had better baseline and posttreatment overall QOL compared to p16-negative patients. The overall and category specific QOL scores for p16-positive patients were not affected by primary treatment modality. Level of Evidence 4. Laryngoscope, 124:1592-1597, 2014

KW - head and neck squamous cell carcinoma

KW - HPV

KW - p16

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=84903143448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903143448&partnerID=8YFLogxK

U2 - 10.1002/lary.24508

DO - 10.1002/lary.24508

M3 - Article

VL - 124

SP - 1592

EP - 1597

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 7

ER -